BiotechTube
Home/Neovii Biotech/Alfred Doucette
AD

Alfred Doucette

Chief Financial Officer

Neovii Biotech

Therapeutic Areas

Organ TransplantationHematology/Oncology

Neovii Biotech Pipeline

DrugIndicationPhase
Grafalon® (ATLG)Prophylaxis of acute rejection in organ transplantation; Hematology/Oncology (e.g., stem cell transplantation conditioning)Approved

Leadership Team at Neovii Biotech

DF
Dr. Frédéric Prince
CEO and General Manager
SH
Sebastian Hofmann
Vice President, Managing Director & Country Head Germany
View full Neovii Biotech profile